Is Tenax Therapeutics Inc (TENX) overvalued? · P/E 3.4, $24.1M cap
Tenax Therapeutics Inc (TENX) is a biotechnology company listed on US.
This page asks whether Tenax Therapeutics Inc (TENX) looks expensive on cached numbers — not a short thesis.
Latest reported TENX revenue for 2025-09-30 was $0. Net income was -$37.1M. TENX currently screens at market cap $24.1M and trailing P/E 3.4.
TENX currently screens at market cap $24.1M and trailing P/E 3.4. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TENX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TENX stock page for the full model, not this heading.
Not investment advice.